NASDAQ:MDGL Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis $378.64 -18.10 (-4.56%) Closing price 11/20/2026 03:59 PM EasternExtended Trading$393.45 +14.81 (+3.91%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MDGL alerts:Sign Up Key Stats Today's Range$377.90▼$399.4350-Day Range$378.64▼$540.0652-Week Range$353.54▼$615.00Volume327,830 shsAverage Volume617,116 shsMarket Capitalization$8.80 billionP/E RatioN/ADividend YieldN/APrice Target$710.93Consensus RatingModerate Buy Company Overview Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis. Madrigal’s work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy. Its commercial activities include bringing the medicine to patients in the United States.AI Generated. May Contain Errors. Read More Madrigal Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreMDGL MarketRank™: 3.87666433076 of 5 starsMadrigal Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 105th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 13 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialMadrigal Pharmaceuticals has a consensus price target of $710.93, representing about 87.8% upside from its current price of $378.64.Amount of Analyst CoverageMadrigal Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Madrigal Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($2.08) to $7.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Madrigal Pharmaceuticals is -63.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Madrigal Pharmaceuticals is -63.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMadrigal Pharmaceuticals has a P/B Ratio of 14.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.16% of the float of Madrigal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMadrigal Pharmaceuticals has a short interest ratio ("days to cover") of 7.64.Change versus previous monthShort interest in Madrigal Pharmaceuticals has recently decreased by 2.65%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMadrigal Pharmaceuticals does not currently pay a dividend.Dividend GrowthMadrigal Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.26 News SentimentMadrigal Pharmaceuticals has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Madrigal Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest12 people have searched for MDGL on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $28,352,628.00 in company stock, which represents 0.3223% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Madrigal Pharmaceuticals insiders have bought 425.07% more of their company's stock than they have sold. Specifically, they have bought $35,022,670.00 in company stock and sold $6,670,042.00 in company stock.Percentage Held by Insiders17.60% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Madrigal Pharmaceuticals' insider trading history. Receive MDGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDGL Stock News HeadlinesMDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLPNovember 20 at 10:26 AM | globenewswire.comMDGL INVESTIGATION NOTICE: Hagens Berman, National Securities Law Firm, Investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) Following Whistleblower Allegations of Clinical Data Integrity ConcernsNovember 19 at 12:04 PM | prnewswire.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 22 at 1:00 AM | Profits Run (Ad)Sonic Incytes Medical Corp. Announces Multi-Year Partnership With Madrigal Pharmaceuticals, Inc. To Advance Non-Invasive Liver Assessment In MASHNovember 19 at 9:56 AM | marketscreener.comMMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)November 18, 2026 | globenewswire.comKaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law ViolationsNovember 18, 2026 | globenewswire.comMDGL Investigation Reminder: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLPNovember 17, 2026 | prnewswire.comMadrigal Pharmaceuticals (NASDAQ:MDGL) General Counsel Sells $430,800.00 in StockNovember 7, 2026 | insidertrades.comSee More Headlines MDGL Stock Analysis - Frequently Asked Questions How have MDGL shares performed this year? Madrigal Pharmaceuticals' stock was trading at $582.34 on January 1st, 2026. Since then, MDGL shares have decreased by 35.0% and is now trading at $378.6410. How were Madrigal Pharmaceuticals' earnings last quarter? Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its quarterly earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, beating analysts' consensus estimates of ($1.09) by $2.92. The biopharmaceutical company had revenue of $431.27 million for the quarter, compared to the consensus estimate of $404.17 million. Madrigal Pharmaceuticals had a negative trailing twelve-month return on equity of 27.08% and a negative net margin of 10.89%. Read the conference call transcript. Who are Madrigal Pharmaceuticals' major shareholders? Madrigal Pharmaceuticals' top institutional shareholders include State Street Corp (2.56%), William Blair Investment Management LLC (1.45%), First Trust Advisors LP (0.88%) and Pictet Asset Management Holding SA (0.80%). Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, William John Sibold, Paul A Friedman, Richard S Levy, Brian Joseph Lynch, Carole Huntsman, Mardi Dier, Fred B Craves, Shannon T Kelley, David Soergel, Robert E Waltermire, Kenneth Bate and James M Daly. View institutional ownership trends. How do I buy shares of Madrigal Pharmaceuticals? Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Madrigal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include Viking Therapeutics (VKTX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Tesla (TSLA), Incyte (INCY) and Intel (INTC). Company Calendar Last Earnings11/03/2026Today11/22/20269th Annual Evercore ISI HealthCONx Conference12/01/202638th Annual Healthcare Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 MDGL's financial health is in the Yellow zone, according to TradeSmith. MDGL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MDGL CIK1157601 Webwww.madrigalpharma.com Phone(267) 824-2827Fax781-274-8228Employees915Year Founded2011Price Target and Rating Average Price Target for Madrigal Pharmaceuticals$710.93 High Price Target$962.00 Low Price Target$542.00 Potential Upside/Downside+87.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($5.98) Trailing P/E RatioN/A Forward P/E Ratio51.87 P/E GrowthN/ANet Income-$288.28 million Net Margins-10.89% Pretax Margin-10.89% Return on Equity-27.08% Return on Assets-12.04% Debt Debt-to-Equity Ratio0.54 Current Ratio3.05 Quick Ratio2.78 Sales & Book Value Annual Sales$958.40 million Price / Sales9.18 Cash FlowN/A Price / Cash FlowN/A Book Value$26.99 per share Price / Book14.03Miscellaneous Outstanding Shares23,230,000Free Float19,142,000Market Cap$8.80 billion OptionableOptionable Beta-0.98 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:MDGL) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.